Sign in
TerminatedNo phase

Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients with Endometriosis.

Key facts

Who runs it
Medstar Health Research Institute
Where
McLean, Mitchellville, Rockville, and Washington D.C., United StatesSee the 6 sites
Trial code
Status
Terminated
People taking part
6 people enrolled
Started
2 May 2023
Ended
1 Jul 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Transvaginal photobiomodulation
  • Sham therapy
Record updated
19 February 2025
Why it stopped
Study unable to be conducted with resources at site.

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Proficient English-speaking females
  • Pathology proven endometriosis, >6 weeks from prior pelvic surgery
  • Current dyspareunia

Who cannot take part

  • Currently taking light-sensitizing drugs
  • History of or active treatment for pelvic malignancy
  • Unable to comply with study protocol
  • Pregnant or attempting to become pregnant

Where in United States

  • MedStar McLean ClinicMcLean, United States
  • MedStar Mitchellville ClinicMitchellville, United States
  • MedStar Rockville ClinicRockville, United States
  • MedStar Georgetown University HospitalWashington D.C., United States
  • MedStar Lafayette CenterWashington D.C., United States
  • MedStar Washington Hospital CenterWashington D.C., United States

About the trial

What the trial wants to find out

Dyspareunia is defined as pain with penetrative sexual intercourse. Women with endometriosis have a nine-fold increased risk of dyspareunia, when compared to the general female population.

Read full original descriptionShow less

A prospective single-blinded randomized controlled trial will be performed evaluating the change in pelvic pain and sexual satisfaction scores from baseline to 6 weeks after treatment with transvaginal photobiomodulation therapy or sham therapy. Treatment will involve 9 planned treatment sessions over 3-4 weeks. 40 women will be included in the study.

The 2 groups in the trial

  • Transvaginal photobiomodulationExisting treatment, for comparison

    Participants will undergo active transvaginal photobiomodulation therapy per clinic protocol, using the SoLa Pelvic Therapy system. This includes 9 treatments, each lasting about 3-5 minutes. A sterile narrow vaginal probe is inserted into the vagina, the low-level laser is activated, and the probe is slowly moved along the vaginal walls for the indicated period of time, via a surface area power calculation based on the measured vaginal length at the beginning of the procedure. The 9 treatments must be completed in 3-4 weeks. Intervention: Active SoLa Low-level laser therapy

  • Sham treatmentSham treatment, for comparison

    Participants will undergo sham transvaginal photobiomodulation therapy, following the same protocol as the active arm, without activation of the machine. This includes 9 treatments, lasting 3-5 minutes each. A sterile narrow vaginal probe is inserted into the vagina, the machine is NOT activated, and the inactive probe is slowly moved along the vaginal walls for 3-5 minutes. The 9 treatments must be completed in 3-4 weeks. Intervention: Mock treatment with inactivated probe

    Treatment: Sham therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Transvaginal Photobiomodulation for the Treatment of Dyspareunia in Endometriosis Patients: a Randomized Controlled Trial
Record updated
19 February 2025